H.C. Wainwright downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the company said it is exploring strategic alternatives. No agreement for any strategic transaction has been reached and no timetable has been set for the strategic review process, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Neutral from Buy at Chardan
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
- Needham downgrades Clearside on ‘disappointing’ decision to explore options
- Clearside Biomedical downgraded to Hold from Buy at Needham